Degraded GHK-Cu = less active peptide than the label suggests
The STEP trials demonstrated that semaglutide monotherapy achieves maximal weight loss outcomes when combined with basic dietary and activity modifications
who found higher SOD activity in patients with a lower lesion load on T2

Metabolism & Elimination Limited characterization of specific metabolic pathways has been published for both peptides: CJC-1295 (NO DAC): Peptidase-mediated degradation represents primary metabolic pathway Four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV Metabolites and degradation products not fully characterized in published literature Clearance from circulation within hours despite sustained pharmacodynamic effects Ipamorelin: Clearance of 0.078 L/h/kg in human pharmacokinetic studies Rapid elimination from plasma following distribution phase Metabolic pathways likely involve proteolytic cleavage at peptide bonds No significant accumulation observed with repeated dosing in animal models A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-lives (30 minutes to 2 hours), growth hormone secretory effects persist for 6+ hours, suggesting either active metabolites, tissue retention, or persistent receptor signaling cascade activation

Your age, diet, medical history, and even your medications can all impact how well your body processes this essential nutrient
Moreover, another study demonstrated that extracellular vesicles of specific bacterial taxa could serve as potential biomarkers at different taxonomic levels [189]